NCT04318405View on ClinicalTrials.gov

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).

CompletedOBSERVATIONAL
Enrollment

327

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Iron-Deficiency AnemiaIron-Deficiency
Interventions
DRUG

Iron isomaltoside 1000

Observation of real-life treatment with iron isomaltoside 1000 / Iron Derisomaltose 1000

Trial Locations (21)

Unknown

21, Basel

9, Basel

1, Bern

15, Biel

19, Brugg

18, Gossau

11, Kreuzlingen

12, Kreuzlingen

8, Kreuzlingen

5, Liestal

20, Opfikon

16, Rheinfelden

13, Sankt Gallen

17, Sankt Gallen

7, Sion

6, Spreitenbach

14, Steinach

10, Wettingen

3, Wohlen

2, Zurich

4, Zurich

Sponsors
All Listed Sponsors
lead

Pierre Fabre Pharma AG

INDUSTRY

NCT04318405 - Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). | Biotech Hunter | Biotech Hunter